Please assess the completion status of the following clinical trial:

Trial Title: Long-term Safety and Tolerability of 0.5 mg Fingolimod in Patients With Relapsing Forms of Multiple Sclerosis

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Key Inclusion Criteria:~- Patients who have completed selected ongoing or planned trials with FTY720.~Key Exclusion Criteria:~* Premature permanent discontinuation of a previous fingolimod study.~* Pregnant or nursing (lactating) women.~* Women of child-bearing potential, UNLESS they are using two birth control methods, at least 1 of which must be hormonal contraception, tubal sterilization, partner's vasectomy or intrauterine device.~* Chronic disease of the immune system, other than multiple sclerosis, which may require immunosuppressive treatment.~* Diabetic patients with moderate or severe non-proliferative diabetic retinopathy or proliferative diabetic retinopathy and uncontrolled diabetic patients with HbA1c \> 8%.~* Active systemic bacterial, viral or fungal infections, or known to have AIDS, Hepatitis B, Hepatitis C infection or have positive HIV antibody, Hepatitis B surface antigen or Hepatitis C antibody tests.~* Previous treatment with cladribine, cyclophosphamide or mitoxantrone.~* Treatment with immunoglobulins and/or monoclonal antibodies (including Natalizumab) in the past 3 months during the previous fingolimod study:~* Any of the following cardiovascular conditions that have developed during the previous fingolimod study:~  * Myocardial infarction within the past 6 months prior to entry in the extension study or with current unstable ischemic heart disease;~ * Cardiac failure (Class III, according to New York Heart Association Classification) or any severe cardiac disease as determined by the investigator;~ * Arrhythmia requiring current treatment with Class III antiarrhythmic drugs (e.g., amiodarone, bretylium, sotalol, ibutilide, azimilide, dofetilide)~ * History or presence of a third degree AV block~ * Proven history of sick sinus syndrome or sino-atrial heart block~ * Known history of angina pectoris due to coronary spasm or Raynaud's phenomenon~* Any of the following pulmonary conditions during the previous fingolimod study:~  * Severe respiratory disease or pulmonary fibrosis diagnosed (during the previous fingolimod study)~ * Active tuberculosis~* Alcohol abuse, chronic liver disease during the previous fingolimod study.~The patient must have participated in a previous fingolimod trial to be eligible to participate in this trial.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Fingolimod 0.5 mg/day (Type: EXPERIMENTAL): Open-label fingolimod 0.5 mg, taken orally once daily

Based on this trial design, predict the completion outcome and termination type (if applicable).